Gene
FGF3
FGF3 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Actionable biomarkers (2), Trial mentions (56), Target-disease associations (115), and 5 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
4 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention FGF3. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 1 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 1 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 1 of 8,738 | 0.01% | not measured | |
| 2025 | 1 of 8,875 | 0.01% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 3 of 8,275 | 0.04% | 5 of 11,460 | 0.04% |
| 2022 | 0 of 8,285 | 0.00% | 7 of 13,598 | 0.05% |
| 2021 | 0 of 8,692 | 0.00% | 5 of 15,045 | 0.03% |
| 2020 | 3 of 7,640 | 0.04% | 1 of 14,459 | 0.01% |
| 2019 | 0 of 7,300 | 0.00% | 5 of 12,159 | 0.04% |
| 2018 | 4 of 6,927 | 0.06% | 4 of 11,854 | 0.03% |
| 2017 | 6 of 6,558 | 0.09% | 3 of 11,595 | 0.03% |
Showing 10 of 37 years.
Actionable biomarkers (2)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| FGF3 amplification | Lucitanib | response-associated | breast adenocarcinoma | Cancer Genome Interpreter |
| FGF3 amplification | Dovitinib | response-associated | breast adenocarcinoma | Cancer Genome Interpreter |
Trial mentions (56)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT00892190 | Trial eligibility (AACT) |
| NCT00071799 | Trial eligibility (AACT) |
| NCT04644016 | Trial eligibility (AACT) |
| NCT01795924 | Trial eligibility (AACT) |
| NCT01050946 | Trial eligibility (AACT) |
Showing 5 of 56 trial mentions.
Target-disease associations (115)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 7q31 microdeletion syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Autosomal recessive cerebellar ataxia - blindness - deafness | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| BOR syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Branchio-otic syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Choroideremia - deafness - obesity | disorder of visual system | Mouse knockout (IMPC) |
Showing 5 of 115 associations.
Vendor sourcing (168)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant has been observed in at least two similarly affected unrelated individuals (PMID: 33187236). It has been reported to be in trans with a pathogeni... | View ClinVar record SCV002318908.1 |
| AbbVie Inc. | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Histological or cytological confirmation of one of the following (Arms A, B and D): * Relapsed or refractory acute myelogenous leukemia (AML), untr... | View trial NCT01110473 |
| AbbVie Inc. | Trial sponsor | Mentioned in trial textTrial free-text mention | INT2 | View trial NCT01110473 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.635G>A (p.R212Q) alteration is located in exon 3 (coding exon 3) of the FGF3 gene. This alteration results from a G to A substitution at nucleotide pos... | View ClinVar record SCV003553884.2 |
| Biosuccess Biotech Co., Ltd. | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : * Patient has newly diagnosed AML and refuses or is not eligible for treatment with aggressive chemotherapy and/or SCT; OR AML and has relapsed or been re... | View trial NCT01795924 |
Showing 5 of 168 sourcing records.
Trial-cited literature (45)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Effectiveness of IVIG on Non-Length-Dependent Skin Biopsies in Small Fiber Neuropathy With Plexin D1, Trisulfated Heparin Disaccharide, and Fibroblast Growth Factor Receptor 3 Autoantibodies. | Journal of clinical neuromuscular disease | 2024 | 13 |
| Lifetime impact of achondroplasia study in Europe (LIAISE): findings from a multinational observational study. | Orphanet journal of rare diseases | 2023 | 35 |
| Potential value of ctDNA monitoring in metastatic HR + /HER2 - breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial. | BMC medicine | 2023 | 20 |
| First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors. | Targeted oncology | 2023 | 7 |
| Pharmacokinetics, pharmacodynamics and efficacy of pemigatinib (a selective inhibitor of fibroblast growth factor receptor 1-3) monotherapy in Chinese patients with advanced solid tumors: a phase i clinical trial. | Investigational new drugs | 2023 | 4 |
Showing 5 of 45 papers.
Protein variant mentions (4)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.G34C | 1 | 2015 | PMID 25741868 |
| p.K101N | 1 | 2016 | PMID 26467025 |
| p.L56F | 1 | 2015 | PMID 25741868 |
| p.R104* | 1 | 2015 | PMID 25741868 |
Literature-extracted relations (10)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Small Fiber Neuropathy | Disease | associate |
Effectiveness of IVIG on Non-Length-Dependent Skin Biopsies in Small Fiber Neuropathy With Plexin D1, Trisulfated Heparin Disaccharide, and Fibroblast Growth Factor Receptor 3 Autoantibodies. | 2024 |
| Rotator Cuff Injuries | Disease | associate |
Genetic and familial predisposition to rotator cuff disease: a systematic review. | 2017 |
| Carcinoma, Hepatocellular | Disease | associate |
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. | 2015 |
| Neoplasms | Disease | associate |
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. | 2015 |
| Muscular Atrophy, Spinal | Disease | associate |
Antifibroblast growth factor receptor 3 antibodies identify a subgroup of patients with sensory neuropathy. | 2015 |
Showing 5 of 10 relation assertions.
Organizations publishing (102)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| The University of Texas System | Academic | 6 | 2015 to 2022 |
| CERCA Institution | Government | 3 | 2014 to 2017 |
| Harvard Medical School | Academic | 3 | 2021 to 2022 |
| Assistance Publique – Hôpitaux de Paris | Hospital | 2 | 2015 to 2016 |
| Columbia University | Academic | 2 | 2015 to 2021 |
Showing 5 of 102 organizations.
Where FGF3 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of ear
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- phenotype
106 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, assay-provider ledger, and human sample screening reference.